Palantir Earnings Lift 2026 Guidance

Palantir earnings showed Q4 2025 revenue strength and raised 2026 guidance, prompting traders to reprice and shift flows into growth and defense exposure.

March 02, 2026·2 min read
View all news articles
Flat vector server core expanding to symbolize Palantir earnings growth and larger contract backlog with subtle shadow lift

KEY TAKEAWAYS

  • Q4 2025 revenue reached $1.4 billion, up 70.0% year-over-year.
  • Guidance sets 2026 revenue at $7.2 billion, implying about 61.0% growth.
  • Backlog rose to about $4.4 billion, including a potential $10.0 billion U.S. Army framework.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Palantir Technologies reported Q4 2025 results prior to February 25, 2026, showing rapid revenue growth that led management to raise its 2026 revenue outlook. Growth accelerated as U.S. commercial adoption and defense contracts expanded the company’s profile.

Quarterly Results and 2026 Guidance

Palantir posted Q4 2025 revenue of $1.4 billion, a 70.0% increase year-over-year, driven largely by a surge in commercial sales. U.S. commercial revenue rose 137.0% year-over-year and 28.0% quarter-over-quarter, expanding the company’s commercial footprint. U.S. government revenue grew 66.0% year-over-year and 17.0% quarter-over-quarter, pushing total U.S. business revenue above $1 billion for the quarter.

Management set 2026 revenue guidance at about $7.2 billion, implying 61.0% growth. U.S. commercial sales are expected to exceed $3.1 billion, with adjusted operating income projected near $4.1 billion. The outlook assumes continued U.S. market acceleration, adoption of Palantir’s AIP offering, and steady contract execution.

Defense and Commercial Contract Growth

Palantir’s total contract value reached a record $4.3 billion in Q4, while remaining deal value climbed 145.0% to roughly $4.4 billion, expanding backlog and revenue visibility. This backlog includes a potential U.S. Army enterprise agreement valued at $10.0 billion over 10 years under an existing enterprise framework.

In December 2025, the U.K. Ministry of Defence awarded Palantir a £240 million, three-year contract without tender to provide data analytics supporting strategic, tactical, and live operational decision-making.

Commercial momentum was evident in client growth and deal size. The customer base increased 34.0% year-over-year to 954 clients. The company closed 180 deals at or above $1 million, including 84 above $5 million and 61 above $10 million. In February 2026, Airbus extended a multi-year partnership for its Skywise aviation data platform.

Management’s 2026 guidance reflects expectations of sustained U.S. market growth, continued AIP adoption, and consistent contract execution.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Nexstar Tegna Merger Approved Amid Lawsuits

Nexstar Tegna Merger Approved Amid Lawsuits

Nexstar Tegna merger closed with DOJ clearance and an FCC ownership waiver, creating a national broadcaster and raising litigation risk for investors.

U.S. Stocks Selloff Amid Middle East Energy Attacks

U.S. Stocks Selloff Amid Middle East Energy Attacks

U.S. Stocks Selloff after strikes on Middle East energy sites lifted oil and gas prices, raising inflation risk and tightening the Fed outlook.

MLB Polymarket Partnership Adds CFTC Oversight

MLB Polymarket Partnership Adds CFTC Oversight

MLB Polymarket partnership with a CFTC MOU requires integrity controls and bars high-risk markets, narrowing tradable baseball contracts and altering flow.

OpenAI Acquires Astral to Boost Codex

OpenAI Acquires Astral to Boost Codex

OpenAI acquires Astral, folding uv, ruff and ty into Codex to accelerate the AI coding assistant and likely shift developer tooling positioning.

Wegovy HD FDA Approval Bolsters Novo Nordisk

Wegovy HD FDA Approval Bolsters Novo Nordisk

Wegovy HD FDA approval follows STEP UP results and clears an April 2026 U.S. launch, shifting Novo Nordisk's commercial access and investor positioning.

Uber Rivian Robotaxi Investment

Uber Rivian Robotaxi Investment

Uber Rivian Robotaxi Investment ties funding to regulatory approval and autonomy milestones, reshaping rollout timing and capital risk.